PDF (Download) |
- Prickly Pear Cactus (Opuntia ficus-indica)
- Metabolic Syndrome
- NeOpuntia®
| Date: 11-25-2008 | HC# 060682-365 |
Re: Prickly Pear Pads Improve Subgroup Paramenters of Metabolic Syndrome in Women
Linarès E, Thimonier C, Degre M. The effect of NeOpuntia® on blood lipid parameters-risk factors for the metabolic syndrome (syndrome X). Adv Ther. Sep-Oct 2007;24(5): 1115-1125.
The fruit and cladodes (pads) of prickly pear
cactus (Opuntia ficus-indica),
commonly known as tunas and nopales, respectively, are important in food and
traditional medicine throughout the American Southwest, Latin America, and
elsewhere. Pre-clinical studies have indicated that consumption of prickly pear
cactus pads may improve cholesterol levels and clinical studies show reductions
in blood glucose, but there have been few clinical trials addressing the impact
on blood lipids. NeOpuntia® (Bio Serae Laboratories, Bram, France)
is a dietary supplement manufactured from dehydrated prickly pear cactus
cladodes. This randomized, double-blind, placebo-controlled clinical trial was
designed to examine the effects of NeOpuntia on parameters associated with
metabolic syndrome, also known as syndrome X.
The study was conducted in Saint-Gregoire,
France from May to June 2006 and included women with body mass indices between
25 and 40 kg/m2 who had been diagnosed with metabolic syndrome
according to the International Diabetes Federation 2005 guidelines based on
abdominal obesity and defined excesses in at least 2 of the following 4
criteria: blood pressure and blood levels of glucose, triglycerides, and high
density lipoprotein cholesterol (HDL-C). A total of 68 women were included in
the intention to treat (ITT) analysis and 59 completed the study. According to
the authors, the drop-outs were "mainly due to personal reasons." The
subjects were randomized to receive either 1.6 g NeOpuntia capsules (n=35) or a
placebo (n=33) 3 times daily 0.5-1 hour following meals for 6 weeks. Subjects
were instructed on how to follow an average 2000 Calorie balanced diet with at
least 30 minutes of physical activity daily.
Compliance was good in 90% of the subjects in
both groups. There were no severe adverse effects associated with NeOpuntia or
the placebo. There were 2 cases of gastric disorders leading to non-tolerance
in the NeOpuntia group and 2 cases (1 gastric disorder and 1 insomnia) leading
to non-tolerance in the placebo group. There were 7 milder adverse events,
including digestive problems and constipation described by 7 subjects in the
NeOpuntia group and 5 in the placebo group.
From baseline to day 42, decreases in
low-density lipoprotein (LDL) cholesterol and total cholesterol were observed
in both groups, including a borderline statistically significant decrease in
LDL cholesterol in the placebo group (P=0.05). The decreases could be due to
adherence to the diet and physical activity. Triglycerides decreased and HDL-C
increased in the NeOpuntia group also without reaching statistical
significance. By the end of the study, 92% of placebo group subjects still had
metabolic syndrome, while only 61% of the subjects in the NeOpuntia group were
still diagnosed with the disorder. This resulted from improvements in the
criteria for metabolic syndrome that no longer met required parameters for HDL
cholesterol (n=1), triglycerides (n=2), blood pressure (n=10), and waist
circumference (n=2) that were achieved in the NeOpuntia group. Blood pressure
(n=14) and triglyceride levels (n=1) were also improved in the placebo group,
but levels of fasting glucose (n=2) and HDL-C (n=1) worsened and fell within
the metabolic syndrome parameters. In subjects with total cholesterol ≥ 2.40
g/L (n=24), the NeOpuntia group showed a statistically significant greater
increase in HDL "good" cholesterol (P=0.041) than placebo. In
subjects over the age of 45, treatment with NeOpuntia also resulted in a
significantly greater increase in HDL cholesterol (P=0.029), when compared to
the placebo group.
The increases in HDL-C are especially
important in postmenopausal women whose risk of cardiovascular disease
increases as it typically declines. HDL-C increase could be attributed in part
to interference with lipid absorption by prickly pear fiber. Antioxidants found
in prickly pear cladodes may also contribute to the effects observed in this
study. The authors conclude "the observed effect of NeOpuntia on HDL-C
[cholesterol] levels, as well as other blood lipid parameters, shows a clear
advantage for this nutritional supplement, compared with placebo, for the
management of metabolic syndrome." More research, including a clinical
trial with a larger sample size and confirmation of possible mechanisms of
action, is needed.
—Marissa
Oppel, MS |